Humana (NYSE:HUM) PT Lowered to $326.00

Humana (NYSE:HUM) had its target price cut by UBS Group from $334.00 to $326.00 in a research report report published on Thursday morning, Benzinga reports. They currently have a neutral rating on the insurance provider’s stock.

A number of other equities research analysts have also recently weighed in on the company. TD Cowen decreased their price objective on Humana from $427.00 to $396.00 and set a buy rating for the company in a research note on Tuesday, April 2nd. Wells Fargo & Company reduced their target price on Humana from $413.00 to $350.00 and set an overweight rating on the stock in a research report on Monday, April 8th. Raymond James assumed coverage on Humana in a research report on Friday, March 22nd. They set a market perform rating on the stock. The Goldman Sachs Group reduced their target price on Humana from $450.00 to $385.00 and set a buy rating on the stock in a research report on Wednesday, April 3rd. Finally, Mizuho reduced their target price on Humana from $550.00 to $400.00 and set a buy rating on the stock in a research report on Friday, January 26th. Eleven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and an average target price of $433.74.

Humana Stock Down 1.1 %

Shares of HUM stock traded down $3.53 during mid-day trading on Thursday, hitting $307.88. The stock had a trading volume of 468,188 shares, compared to its average volume of 1,985,533. Humana has a 12-month low of $299.23 and a 12-month high of $541.21. The firm has a market capitalization of $37.15 billion, a P/E ratio of 19.18, a price-to-earnings-growth ratio of 1.85 and a beta of 0.45. The firm’s 50-day moving average is $328.56 and its two-hundred day moving average is $395.71. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.59.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. The firm had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. During the same period in the prior year, the business posted $9.38 EPS. On average, analysts predict that Humana will post 16.06 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.15%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s dividend payout ratio (DPR) is 22.04%.

Insider Buying and Selling

In related news, Director Jorge S. Mesquita bought 545 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were purchased at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the acquisition, the director now directly owns 2,578 shares in the company, valued at $946,358.02. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.32% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Humana

A number of hedge funds have recently bought and sold shares of the business. SYSTM Wealth Solutions LLC lifted its position in shares of Humana by 20.3% in the first quarter. SYSTM Wealth Solutions LLC now owns 2,967 shares of the insurance provider’s stock valued at $1,030,000 after acquiring an additional 501 shares in the last quarter. Mesirow Financial Investment Management Inc. purchased a new position in shares of Humana in the first quarter valued at approximately $297,000. Carr Financial Group Corp purchased a new position in shares of Humana in the first quarter valued at approximately $348,000. KG&L Capital Management LLC purchased a new position in shares of Humana in the first quarter valued at approximately $457,000. Finally, Lindbrook Capital LLC lifted its position in shares of Humana by 23.6% in the first quarter. Lindbrook Capital LLC now owns 1,080 shares of the insurance provider’s stock valued at $374,000 after acquiring an additional 206 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.